CYP2D6 polymorphisms and their influence on risperidone treatment

References

• CorrellCUAntipsychotic polypharmacy, Part 2: why use 2 antipsychotics when 1 is not good enough?J Clin Psychiatry200869586086118681762
   PubMed Web of Science ®Google Scholar
• HongCJLiouYJBaiYMChenTTWangYCTsaiSJDopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatmentPharmacogenet Genomics201020635936620375926
   PubMed Web of Science ®Google Scholar
• LaneHYLeeCCLiuYCChangWHPharmacogenetic studies of response to risperidone and other newer atypical antipsychoticsPharmacogenomics20056213914915882132
   PubMed Web of Science ®Google Scholar
• WangJSRuanYTaylorRMDonovanJLMarkowitzJSDeVaneCLThe brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoproteinInt J Neuropsychopharmacol20047441541915683552
   PubMed Web of Science ®Google Scholar
• DoranAObachRSSmithBJThe impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse modelDrug Metab Dispos200533116517415502009
   PubMed Web of Science ®Google Scholar
• FangJBourinMBakerGBMetabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4Naunyn Schmiedebergs Arch Pharmacol1999359214715110048600
   PubMed Web of Science ®Google Scholar
• BruntonPJDonadioMVRussellJASex differences in prenatally programmed anxiety behaviour in rats: differential corticotropin-releasing hormone receptor mRNA expression in the amygdaloid complexStress201114663464321854167
   PubMed Web of Science ®Google Scholar
• MasriBSalahpourADidriksenMAntagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychoticsProc Natl Acad Sci U S A200810536136561366118768802
   PubMed Web of Science ®Google Scholar
• ItoHTakanoHTakahashiHEffects of the antipsychotic risperidone on dopamine synthesis in human brain measured by positron emission tomography with L-[beta-11C]DOPA: a stabilizing effect for dopaminergic neurotransmission?J Neurosci20092943137301373419864585
   PubMed Web of Science ®Google Scholar
• Abou El-MagdRMParkHKKawazoeTThe effect of risperidone on D-amino acid oxidase activity as a hypothesis for a novel mechanism of action in the treatment of schizophreniaJ Psychopharmacol20102471055106719329549
   PubMed Web of Science ®Google Scholar
• BymasterFPCalligaroDOFalconeJFRadioreceptor binding profile of the atypical antipsychotic olanzapineNeuropsychopharmacology199614287968822531
   PubMed Web of Science ®Google Scholar
• RichelsonESouderTBinding of antipsychotic drugs to human brain receptors focus on newer generation compoundsLife Sci2000681293911132243
   PubMed Web of Science ®Google Scholar
• HeimMHMeyerUAEvolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6Genomics199214149581358797
   PubMed Web of Science ®Google Scholar
• EichelbaumMBaurMPDenglerHJChromosomal assignment of human cytochrome P-450 (debrisoquine/sparteine type) to chromosome 22Br J Clin Pharmacol19872344554583472585
   PubMed Web of Science ®Google Scholar
• ZangerUMRaimundoSEichelbaumMCytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistryNaunyn Schmiedebergs Arch Pharmacol20043691233714618296
   PubMed Web of Science ®Google Scholar
• KimuraSUmenoMSkodaRCMeyerUAGonzalezFJThe human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogeneAm J Hum Genet19894568899042574001
   PubMed Web of Science ®Google Scholar
• HicksJKBishopJRSangkuhlKClinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitorsClin Pharmacol Ther201598212713425974703
   PubMed Web of Science ®Google Scholar
• LienEASolheimELeaOALundgrenSKvinnslandSUelandPMDistribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatmentCancer Res1989498217521832702659
   PubMed Web of Science ®Google Scholar
• CrewsKRGaedigkADunnenbergerHMClinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 updateClin Pharmacol Ther201495437638224458010
   PubMed Web of Science ®Google Scholar
• HosonoNKatoMKiyotaniKCYP2D6 genotyping for functional-gene dosage analysis by allele copy number detectionClin Chem20095581546155419541866
   PubMed Web of Science ®Google Scholar
• KiyotaniKShimizuMKumaiTKamatakiTKobayashiSYamazakiHLimited effects of frequent CYP2D6*36-*10 tandem duplication allele on in vivo dextromethorphan metabolism in a Japanese populationEur J Clin Pharmacol201066101065106820700584
   PubMed Web of Science ®Google Scholar
• ChamnanphonMPechatananKSirachainanEAssociation of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifenPharmacogenomics Pers Med201363748
   PubMedGoogle Scholar
• SukasemCSirachainanEChamnanphonMImpact of CYP2D6 polymorphisms on tamoxifen responses of women with breast cancer: a microarray-based study in ThailandAsian Pac J Cancer Prev20121394549455323167378
   PubMedGoogle Scholar
• SuwannasriPThongnoppakhunWPramyothinPAssawamakinALimwongseCCombination of multiplex PCR and DHPLC-based strategy for CYP2D6 genotyping scheme in ThaisClin Biochem201144131144115221763299
   PubMed Web of Science ®Google Scholar
• VanwongNNgamsamutNHongkaewYDetection of CYP2D6 polymorphism using Luminex xTAG technology in autism spectrum disorder: CYP2D6 activity score and its association with risperidone levelsDrug metab pharmacokinet201631215616226944100
   PubMed Web of Science ®Google Scholar
• VanwongNNgamsamutNMedhasiSImpact of CYP2D6 polymorphism on steady-state plasma levels of risperidone and 9-hydroxyrisperidone in Thai children and adolescents with autism spectrum disorderJ Child Adolesc Psychopharmacol Epub2016118
   Web of Science ®Google Scholar
• International Breast Cancer Study GroupColleoniMGelberSTamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93J Clin Oncol20062491332134116505417
   PubMed Web of Science ®Google Scholar
• SistonenJSajantilaALaoOCoranderJBarbujaniGFuselliSCYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structurePharmacogenet Genomics20071729310117301689
   PubMed Web of Science ®Google Scholar
• ZhouSFPolymorphism of human cytochrome P450 2D6 and its clinical significance: part IClin Pharmacokinet2009481168972319817501
   PubMed Web of Science ®Google Scholar
• LondinERClarkPSponzielloMKrickaLJFortinaPParkJYPerformance of exome sequencing for pharmacogenomicsPer Med201412210911526257813
   PubMed Web of Science ®Google Scholar
• Affymetrix Available from: http://www.affymetrix.comAccessed June 4, 2016
   Google Scholar
• Database THCPCAN Available from: http://www.cypalleles.ki.se/cyp2d6.htmAccessed June 2, 2016
   Google Scholar
• Ingelman-SundbergMSimSCGomezARodriguez-AntonaCInfluence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspectsPharmacol Ther2007116349652618001838
   PubMed Web of Science ®Google Scholar
• StearnsVJohnsonMDRaeJMActive tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetineJ Natl Cancer Inst200395231758176414652237
   PubMed Web of Science ®Google Scholar
• HertzDLSnavelyACMcLeodHLIn vivo assessment of the metabolic activity of CYP2D6 diplotypes and allelesBr J Clin Pharmacol20158051122113025907378
   PubMed Web of Science ®Google Scholar
• DalenPDahlMLBernal RuizMLNordinJBertilssonL10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genesClin Pharmacol Ther19986344444529585799
   PubMed Web of Science ®Google Scholar
• MellstromBBertilssonLSaweJSchulzHUSjoqvistFE- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylationClin Pharmacol Ther19813021891937249504
   PubMed Web of Science ®Google Scholar
• BertilssonLEichelbaumMMellstromBSaweJSchulzHUSjoqvistFNortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in manLife Sci19802718167316777442467
   PubMed Web of Science ®Google Scholar
• NovalbosJLopez-RodriguezRRomanMGallego-SandinSOchoaDAbad-SantosFEffects of CYP2D6 genotype on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteersJ Clin Psychopharmacol201030550451120814331
   PubMed Web of Science ®Google Scholar
• SakuyamaKSasakiTUjiieSFunctional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57)Drug Metab Dispos200836122460246718784265
   PubMed Web of Science ®Google Scholar
• WillyardCCopy number variations’ effect on drug response still overlookedNat Med201521320625742449
   PubMed Web of Science ®Google Scholar
• BeorisMAmos WilsonJGarcesJALukowiakAACYP2D6 copy number distribution in the US populationPharmacogenet Genomics2016262969926551314
   PubMed Web of Science ®Google Scholar
• ShengHHZengAPZhuWXAllelic distributions of CYP2D6 gene copy number variation in the Eastern Han Chinese populationActa Pharmacol Sin200728227928617241532
   PubMed Web of Science ®Google Scholar
• GaedigkASimonSDPearceREBradfordLDKennedyMJLeederJSThe CYP2D6 activity score: translating genotype information into a qualitative measure of phenotypeClin Pharmacol Ther200883223424217971818
   PubMed Web of Science ®Google Scholar
• BorgesSDestaZLiLQuantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatmentClin Pharmacol Ther2006801617416815318
   PubMed Web of Science ®Google Scholar
• JanssenPANiemegeersCJAwoutersFSchellekensKHMegensAAMeertTFPharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic propertiesJ Pharmacol Exp Ther198824426856932450200
   PubMed Web of Science ®Google Scholar
• MannensGHuangMLMeuldermansWHendrickxJWoestenborghsRHeykantsJAbsorption, metabolism, and excretion of risperidone in humansDrug Metab Dispos1993216113411417507814
   PubMed Web of Science ®Google Scholar
• van BeijsterveldtLEGeertsRJLeysenJERegional brain distribution of risperidone and its active metabolite 9-hydroxyrisperidone in the ratPsychopharmacology1994114153627531352
   PubMed Web of Science ®Google Scholar
• de LeonJSandsonNBCozzaKLA preliminary attempt to personalize risperidone dosing using drug-drug interactions and genetics: part IPsychosomatics200849325827018448784
   PubMed Web of Science ®Google Scholar
• DuJZhangAWangLRelationship between response to risperidone, plasma concentrations of risperidone and CYP3A4 polymorphisms in schizophrenia patientsJ Psychopharmacol20102471115112019395426
   PubMed Web of Science ®Google Scholar
• MasSGassoPBernardoMLafuenteAFunctional analysis of gene expression in risperidone treated cells provide new insights in molecular mechanism and new candidate genes for pharmacogenetic studiesEur Neuropsychopharmacol201323432933722612990
   PubMed Web of Science ®Google Scholar
• CartwrightALWilbyKJCorriganSEnsomMHPharmacogenetics of risperidone: a systematic review of the clinical effects of CYP2D6 polymorphismsAnn Pharmacother201347335036023463739
   PubMed Web of Science ®Google Scholar
• Ingelman-SundbergMGenetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversityPharmacogenomics J20055161315492763
   PubMed Web of Science ®Google Scholar
• Ingelman-SundbergMSimSCPharmacogenetic biomarkers as tools for improved drug therapy; emphasis on the cytochrome P450 systemBiochem Biophys Res Commun20103961909420494117
   PubMed Web of Science ®Google Scholar
• ZhouSFPolymorphism of human cytochrome P450 2D6 and its clinical significance: part IIClin Pharmacokinet2009481276180419902987
   PubMed Web of Science ®Google Scholar
• HicksJKSwenJJThornCFClinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressantsClin Pharmacol Therapeut2013935402408
   PubMed Web of Science ®Google Scholar
• JovanovicNBozinaNLovricMMedvedVJakovljevicMPelesAMThe role of CYP2D6 and ABCB1 pharmacogenetics in drug-naive patients with first-episode schizophrenia treated with risperidoneEur J Clin Pharmacol201066111109111720563569
   PubMed Web of Science ®Google Scholar
• XiangQZhaoXZhouYDuanJLCuiYMEffect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moietyJ Clin Pharmacol201050665966620332423
   PubMed Web of Science ®Google Scholar
• BozinaNJovanovicNLovricMMedvedVClinical significance of a CYP2D6 poor metabolizer – a patient with schizophrenia on risperidone treatmentTher Drug Monit200830674875118806696
   PubMed Web of Science ®Google Scholar
• KnegteringRBaselmansPCasteleinSBoskerFBruggemanRvan den BoschRJPredominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levelsAm J Psychiatry200516251010101215863810
   PubMed Web of Science ®Google Scholar
• MelkerssonKIProlactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metaboliteHum Psychopharmacol200621852953217094165
   PubMed Web of Science ®Google Scholar
• TroostPWLahuisBEHermansMHProlactin release in children treated with risperidone: impact and role of CYP2D6 metabolismJ Clin Psychopharmacol2007271525717224713
   PubMed Web of Science ®Google Scholar
• NgamsamutNHongkaewYVanwongN9-Hydroxyrisperidone-induced hyperprolactinaemia in Thai children and adolescents with autism spectrum disorderBasic Clin Pharmacol Toxicol2016119326727226879343
   PubMed Web of Science ®Google Scholar
• WangLYuLZhangAPSerum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophreniaJ Psychopharmacol200721883784217715206
   PubMed Web of Science ®Google Scholar
• NasrallahHAAtypical antipsychotic-induced metabolic side effects: insights from receptor-binding profilesMol Psychiatry2008131273517848919
   PubMed Web of Science ®Google Scholar
• NasrallahHAMetabolic findings from the CATIE trial and their relation to tolerabilityCNS Spectrums2006117 Suppl 7323916816798
   PubMed Web of Science ®Google Scholar
• LaneHYLiuYCHuangCLRisperidone-related weight gain: genetic and nongenetic predictorsJ Clin Psychopharmacol200626212813416633140
   PubMed Web of Science ®Google Scholar
• CorreiaCTAlmeidaJPSantosPEPharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactionsPharmacogenomics J201010541843019997080
   PubMed Web of Science ®Google Scholar
• KakiharaSYoshimuraRShinkaiKPrediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6Int Clin Psychopharmacol2005202717815729081
   PubMed Web of Science ®Google Scholar
• AlmogueraBRiveiro-AlvarezRLopez-CastromanJCYP2D6 poor metabolizer status might be associated with better response to risperidone treatmentPharmacogenet Genomics2013231162763024026091
   PubMed Web of Science ®Google Scholar
• YoungsterIZachorDAGabisLVCYP2D6 genotyping in paediatric patients with autism treated with risperidone: a preliminary cohort studyDev Med Child Neurol2014561099099424828442
   PubMed Web of Science ®Google Scholar
• FleemanNDundarYDicksonRCytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analysesPharmacogenomics J201111111420877299
   PubMed Web of Science ®Google Scholar
• RavynDRavynVLowneyRNasrallahHACYP450 pharmacogenetic treatment strategies for antipsychotics: a review of the evidenceSchizophr Res20131491–311423870808
   PubMed Web of Science ®Google Scholar
• de LeonJSusceMTPanRMFairchildMKochWHWedlundPJThe CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuationJ Clin Psychiatry2005661152715669884
   PubMed Web of Science ®Google Scholar
• NussbaumLADumitrascuVTudorAGradinaruRAndreescuNPuiuMMolecular study of weight gain related to atypical antipsychotics: clinical implications of the CYP2D6 genotypeRom J Morphol Embryol201455387788425329115
   PubMed Web of Science ®Google Scholar
• EllingrodVLMillerDSchultzSKWehringHArndtSCYP2D6 polymorphisms and atypical antipsychotic weight gainPsychiatr Genet2002121555811901361
   PubMed Web of Science ®Google Scholar
• TurronePKapurSSeemanMVFlintAJElevation of prolactin levels by atypical antipsychoticsAm J Psychiatry2002159113313511772702
   PubMed Web of Science ®Google Scholar
• StevensJRKymissisPIBakerAJElevated prolactin levels in male youths treated with risperidone and quetiapineJ Child Adolesc Psychopharmacol200515689390016379509
   PubMed Web of Science ®Google Scholar
• CalargeCAEllingrodVLAcionLVariants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescentsPharmacogenet Genomics200919537338219339912
   PubMed Web of Science ®Google Scholar
• RokeYvan HartenPNFrankeBGaleslootTEBootAMBuitelaarJKThe effect of the Taq1A variant in the dopamine D(2) receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boysPharmacogenet Genomics201323948749323851570
   PubMed Web of Science ®Google Scholar
• HongkaewYNgamsamutNPuangpetchAHyperprolactinemia in Thai children and adolescents with autism spectrum disorder treated with risperidoneNeuropsychiatr Dis Treat20151119119625653528
   PubMed Web of Science ®Google Scholar
• dos Santos JuniorAHenriquesTBde MelloMPHyperprolactinemia in children and adolescents with use of risperidone: clinical and molecular genetics aspectsJ Child Adolesc Psychopharmacol2015251073874826682995
   PubMed Web of Science ®Google Scholar
• OzdemirVBertilssonLMiuraJCYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6-serotonin-dopamine crosstalk revisitedPharmacogenet Genomics200717533934717429316
   PubMed Web of Science ®Google Scholar
• SukasemCHongkaewYNgamsamutNImpact of pharmacogenetic markers of CYP2D6 and DRD2 on prolactin response in risperidone-treated Thai children and adolescents with autism spectrum disordersJ Clin Psychopharmacol201636214114626872113
   PubMed Web of Science ®Google Scholar
• BernardSNevilleKANguyenATFlockhartDAInterethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implicationsOncologist200611212613516476833
   PubMed Web of Science ®Google Scholar
• PringsheimTPanagiotopoulosCDavidsonJHoJThe Canadian Alliance for Monitoring Effectiveness and Safety of Antipsychotics in Children (CAMESA) Guideline GroupEvidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youthPaediatr Child Health201116958158923115502
   PubMed Web of Science ®Google Scholar
• HaddadPMWieckAAntipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and managementDrugs200464202291231415456328
   PubMed Web of Science ®Google Scholar
• CabaleiroTOchoaDLopez-RodriguezREffect of polymorphisms on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteersHum Psychopharmacol201429545946925042870
   PubMed Web of Science ®Google Scholar
• DodgenTMEloffAMatabogeCRoosLJvan StadenWCPepperMSRisperidone-associated adverse drug reactions and CYP2D6 polymorphisms in a South African cohortAppl Transl Genom20155404626937359
   PubMedGoogle Scholar
• VandenbergheFGuidiMChoongEGenetics-based population pharmacokinetics and pharmacodynamics of risperidone in a psychiatric cohortClin Pharmacokinet201554121259127226129906
   PubMed Web of Science ®Google Scholar
• de LeonJSusceMTPanRMKochWHWedlundPJPolymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illnessJ Clin Psychopharmacol200525544845616160620
   PubMed Web of Science ®Google Scholar
• GaedigkAComplexities of CYP2D6 gene analysis and interpretationInt Rev Psychiatry201325553455324151800
   PubMed Web of Science ®Google Scholar
• StinglJCBrockmollerJVivianiRGenetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain functionMol Psychiatry201318327328722565785
   PubMed Web of Science ®Google Scholar
• HendsetMMoldenEKnapeMHermannMSerum concentrations of risperidone and aripiprazole in subgroups encoding CYP2D6 intermediate metabolizer phenotypeTher Drug Monit2014361808524232129
   PubMed Web of Science ®Google Scholar
• RauTWohllebenGWuttkeHCYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants – a pilot studyClin Pharmacol Ther200475538639315116051
   PubMed Web of Science ®Google Scholar
• AlfaroCLLamYWSimpsonJEreshefskyLCYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlationsJ Clin Pharmacol2000401586610631623
   PubMed Web of Science ®Google Scholar
• BrynneNSvanstromCAberg-WistedtAHallenBBertilssonLFluoxetine inhibits the metabolism of tolterodine-pharmacokinetic implications and proposed clinical relevanceBr J Clin Pharmacol199948455356310583026
   PubMed Web of Science ®Google Scholar
• MannheimerBvon BahrCPetterssonHEliassonEImpact of multiple inhibitors or substrates of cytochrome P450 2D6 on plasma risperidone levels in patients on polypharmacyTher Drug Monit200830556556918728628
   PubMed Web of Science ®Google Scholar
• LisbethPVincentHKristofMBernardSManuelMHugoNGenotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixolEur J Clin Pharmacol201672217518426514968
   PubMed Web of Science ®Google Scholar
• KimKAParkPWLiuKHEffect of rifampin, an inducer of CYP3A and P-glycoprotein, on the pharmacokinetics of risperidoneJ Clin Pharmacol2008481667218094221
   PubMed Web of Science ®Google Scholar
• BesagFMBerryDInteractions between antiepileptic and antipsychotic drugsDrug Safety20062929511816454538
   PubMed Web of Science ®Google Scholar
• LlerenaABereczRDoradoPde la RubiaAQTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrationsJ Psychopharmacol200418218919315260906
   PubMed Web of Science ®Google Scholar
• SteimerWZopfKvon AmelunxenSAllele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizersClin Chem20045091623163315205367
   PubMed Web of Science ®Google Scholar
• LooversHMvan der WeideJImplementation of CYP2D6 genotyping in psychiatryExpert Opin Drug Metabol Toxicol20095910651077
   PubMed Web of Science ®Google Scholar
• KirchheinerJBrosenKDahlMLCYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosagesActa Psychiatr Scand2001104317319211531654
   PubMed Web of Science ®Google Scholar
• BorgesSDestaZJinYComposite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patientsJ Clin Pharmacol201050445045820081063
   PubMed Web of Science ®Google Scholar